key: cord-1048524-364ozve5 authors: Mohamed Khosroshahi, Leila; Rokni, Mohsen; Mokhtari, Tahmineh; Noorbakhsh, Farshid title: Immunology, Immunopathogenesis and Immunotherapeutics of COVID-19; an Overview date: 2021-01-05 journal: Int Immunopharmacol DOI: 10.1016/j.intimp.2020.107364 sha: 8ac58a5be4ba93ccfe457302ef11babf677b5326 doc_id: 1048524 cord_uid: 364ozve5 Coronavirus disease 2019 (COVID-19) infection which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to a “public health emergency of international concern” (PHEIC). The infection is highly contagious, has a high mortality rate, and its pathophysiology remains poorly understood. Pulmonary inflammations with substantial lung damage together with generalized immune dysregulation are major components of COVID-19 pathogenesis. Of these two components, lung damage seems to be, at least in part, a consequence of immune dysregulation. This study revealed that these immune alterations are not merely an association, as it might occur in systemic infection, but, very likely, the core pathogenic element of COVID-19. In addition, management of the immune responses to SARS-CoV-2, which includes enhancing anti-viral immunity while inhibiting systemic inflammation, may be key to successful treatment. Herein, we have reviewed current evidence related to different aspects of COVID-19 immunology, including innate and adaptive immune responses against the virus and mechanisms of virus-induced immune dysregulation. Considering that an effective vaccine is not yet available to the public and current antiviral therapies are chiefly experimental, strategies do immunotherapy for the management of disease have also been reviewed. Understanding the immune dysregulation in COVID-19 is important to develop more effective immunotherapeutics, diagnostic, and prophylactic strategies in this disease. inhibiting systemic inflammation, may be key to successful treatment. Herein, we have reviewed current evidence related to different aspects of COVID-19 immunology, including innate and adaptive immune responses against the virus and mechanisms of virus-induced immune dysregulation. Considering that an effective vaccine is not yet available to the public and current antiviral therapies are chiefly experimental, strategies do immunotherapy for the management of disease have also been reviewed. Understanding the immune dysregulation in COVID-19 is important to develop more effective immunotherapeutics, diagnostic, and prophylactic strategies in this disease. Keywords: SARS-CoV-2, COVID-19, Immune response, Immunotherapy, Immunopathogenesis In December 2019 the first cases of pneumonia caused by an unknown infectious agent were reported in Wuhan, China. The infectious agent was later discovered to be a novel beta coronavirus (β CoV) that was called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), due to its phylogenetic similarity with SARS-CoV. Infections soon became widespread in China and the rest of the world leading to the declaration of a pandemic and a "public health emergency of international concern" (PHEIC) by WHO. The so-called coronavirus disease 2019 (COVID-19) has a higher severity and mortality rate in the elderly, in patients with underlying conditions like hypertension and diabetes, and in people with diminished immune activity [1] . In addition to being a major threat to public health, the pandemic has also affected social life and global economy. Numerous research groups have started investigating potential antiviral agents as well as the possibility to develop a vaccine [2] . Pneumonia associated with lung damage is the major clinicopathological manifestation of COVID-19. Pneumonia varies from mild to severe and pathological findings range from minor serous exudates to pulmonary edema and diffuse alveolar damage. The latter underlies "acute respiratory distress syndrome" (ARDS) which is seen in some patients and might lead to decreased blood O 2 saturation and lifethreatening hypoxemia. Involvement of cardiovascular system in the form of acute myocardial injury, thromboembolism and ischemic events has been reported [3] [4] [5] [6] [7] . Neurological problems including brainstem malfunction occur in some patients and might be responsible for respiratory failure even in the absence of diffuse lung damage [8, 9] . Nephrological and gastrointestinal involvements have also been reported [10, 11] . Co-occurrence of these pathologies can lead to multi-organ failure. Nonetheless, isolated lung damage seems to be the leading cause of COVID-19 fatality [4, 12, 13] . COVID-19 organ/tissue damage is associated with systemic inflammation and the so-called "cytokine release syndrome" (CRS). While coronaviruses have the ability to inflict direct damage to epithelial tissues through epithelial cell injury and necrosis, evidence indicates that immune system activation/perturbation is the major cause of organ/tissue damage in COVID-19 [3] . Studies on patients with COVID- 19 have shown that the virus triggers the release of various inflammatory mediators including inflammatory cytokines that are chiefly produced by monocytes and macrophages [14, 15] . Studies on CRS caused by SARS-CoV-2 infection have been performed on peripheral blood [15] [16] [17] ; nonetheless, it is likely that local concentrations of cytokines are highly enhanced in the lung tissue where alveolar macrophages are faced with a great number of viral particles [3, 18] . This immunological aspect of disease, as well as the urgent need to develop a vaccine, necessitates a deeper understating of COVID-19 immunology. Moreover, using cytokines, specific antibodies or convalescent plasma for disease immunotherapy demands a better understanding of SARS-CoV-2 immune system interactions. In this review, we have aimed to provide an overview of three different but related aspects of COVID-19 immunology; immune response to SARS-CoV-2, mechanisms of immune dysregulation and potential strategies to do immunotherapy for the management of disease. Innate immunity is the first line of host defense and plays a key role in inhibiting the spread of pathogens. Unlike adaptive immunity which works by generating specific receptors (i.e. antibodies or TCRs) against microbial antigens, innate immunity is based on recognizing general molecular patterns which exist in microbial structures [19] . These "pathogen-associated molecular patterns" (PAMPs) are detected by evolutionarily-conserved groups of receptors named PRRs, which include cell surface or endosomal toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG-I) and NOD-like receptors (NLRs). PAMPs associated with SARS-CoV include viral genomic ssRNA and intermediate substances produced during viral replication, i.e. dsRNA, as well as viral proteins. Coronavirus ssRNA and dsRNA molecules could be detected by several endosomal or cytosolic PRRs. Endosomal TLR3 [20] and endosomal TLR7 [21] have both been reported to get activated following coronavirus infection. Likewise, cytoplasmic RNA sensors, RIG-I and melanoma differentiation-associated gene 5 (MDA5), both respond to coronavirus RNAs. Several studies on SARS-CoV and MERS-CoV have shown that RIG-I mediated signaling is an important player in the induction of antiviral interferon responses against these viruses [22, 23] . "Stimulator of interferon genes" (STING) is another PRR which is generally known as a cytosolic DNA sensor, and while coronaviruses lack DNA, SING-mediated signaling has been reported following coronavirus infections [24] . Viral proteins represent a different group of PAMPs. SARS-CoV spike protein is known to interact with TLR2 and activate downstream signaling pathways [25] . SARS-CoV M protein also acts as a cytosolic PAMP and induces TLR-related interferon responses [25] . These PAMP-PRR interactions result in the activation of "inflammation-promoting" transcription factors (TF), including nuclear factor kappa B (NF-κB) and IFN regulatory factor 3 (IRF3). These transcription factors contribute to the expression of type I interferons (IFN-I) and other proinflammatory cytokines [26] . But in comparison to other respiratory viruses, SARS-CoV-2 infection drives a lower antiviral transcriptional response that is marked by low IFN-I and IFN-III levels and elevated chemokine expression, which could explain the proinflammatory disease state associated with COVID-19 [27] . The dysregulated IFN responses are indicative of the effective immunomodulatory strategies used by betacoronaviruses. During the incubation phase that leading to high viral loads, SARS-CoV-2 replicates stealthily in host cells without detectably triggering IFNs. Several conserved proteins of betacoronavirus, predominantly non-structural proteins (nsps), are known to exert direct IFNantagonistic activities. Some modify specific features of the viral RNA (by catalyzing enzyme guanosine-N7 and ribose-2ʹ-O methylation) to avoid recognition by specific PRRs (i.e, nsp14 and nsp16); inhibit the signal transduction mediated by PRRs and by IFNAR, respectively. During SARS-CoV-2 infection, the robust production of pro-inflammatory chemokines and cytokines, with a restricted production of IFNs, by the nucleocapsid protein, suggests effective activation of NF-κB but not that of IRF3 and IRF7. It will be important to determine exactly how SARS-CoV-2 antagonizes IFN induction and IFNAR signaling [28] . Active viral replication also stimulates the production of chemokines including IL8, IP10 and MCP1 [29, 30] , leading to the subsequent influx of neutrophils and monocytes which act as new sources for proinflammatory mediators [26] . Formation of this PAMP-PRR-TF-cytokine axis requires the simultaneous presence of all four elements in a particular cell. Studies on SARS-CoV have demonstrated that the virus infects different cells in respiratory system including airway and alveolar epithelial cells, vascular endothelial cells and macrophages by binding to angiotensin-converting enzyme-2 (ACE2) receptor. SARS-CoV viral particles and genome have also been identified in circulating lymphocytes and monocytes, following the systemic spread of the virus [31] . SARS-CoV-2 uses the same receptor for cell entry, raising the possibility that the same set of cells get targeted in COVID-19 [7] . Of these, macrophages and lymphocytes contain all required molecular elements and are capable of raising strong cytokine and chemokine responses [32] . A different but related aspect of coronavirus immunopathogenesis might originate from the induction of pyroptosis in lymphocytes and macrophages [32] . SARS-CoV Viroporin 3a has been reported to stimulate the NOD-like receptor protein 3 activation (NLRP3) inflammasome and the secretion of IL1β in bone marrowderived macrophages, which might contribute to pyroptosis [33] . Pyroptosis in turn leads to a massive increase in the levels of proinflammatory cytokines (Table 1 ) [34] . Similar to other pathogens, adaptive immune response against viruses can be categorized into humoral and cellular components. Neutralizing antibodies are the key protective players in the extracellular environment while CD8 + cytotoxic T cells have a prominent role against intracellular viruses. Both elements are controlled and regulated by antigen-specific CD4 + T cells. Antigen presentation cells (APCs) present pathogens antigenic peptides in the context of major histocompatibility complex (MHC) molecules. Depending on the MHC molecule, these antigens can be recognized by CD4 + helper or CD8 + cytotoxic T lymphocytes (CTLs). Studies on infectious diseases have repeatedly implicated "human leukocyte antigen" (HLA) as the major candidate for genetic susceptibility to infections [35, 36] . Different HLA alleles might have different binding specificities for microbial peptides and specific HLA haplotypes are linked to susceptibility to different types of infectious agents, e.g. leprosy, hepatitis B, tuberculosis, human immunodeficiency viruses (HIV) and influenza [37] . Recent studies have illustrated the correlation between susceptibility to SARS-CoV and several HLA alleles, e.g. HLA-B*4601, HLA-B*0703, HLA-DR B1*1202 [38] , and HLA-Cw*0801 [39] . HLA alleles including HLA-Cw1502, HLA-DR0301, and HLA-A*0201 are associated with the protection against SARS infection [40] . This information can be useful in devising clinical management strategies as well as predicting vaccination efficacy in various populations. In addition the HLA, polymorphisms in other genes like mannose-binding lectin (MBL) have also been associated with the risk of SARS-CoV infection [41] . Information regarding potential associations between HLA polymorphisms and SAR-CoV-2 susceptibility and/or disease outcome is limited [42] . A recent in silico analysis of virus-MHC binding affinities have shown that SARS-CoV-2 proteome can be successfully presented by diverse HLA alleles, with HLA-B*46:01 allele showing the lowest ability to present SARS-CoV-2 peptides and hence enhancing the vulnerability to SARS-CoV-2. In contrast, HLA-B*15:03 shows the capacity to present conserved SARS-CoV-2 epitopes which could implicate a better immune response [43] . Recent studies on antibody responses in COVID- 19 [44] . Higher IgM/IgG titers were observed in patients with more severe disease. Of 26 patients who were initially seronegative, 7 patients developed IgM antibodies earlier than IgG and 9 patients had simultaneous seroconversion. Interestingly, 10 patients developed IgG before IgM seroconversion [44] . Another study on 112 patients showed that more than 51% of cases were positive for both IgM and IgG, while 41% were only positive for IgG, within 7-10 days after disease onset [45] . A study by Zhao et al on 173 patients reported 82% IgM and 64% IgG seropositivity among patients [46] . In a more recent work, researchers investigated antibody responses against spike protein RBD (receptor binding domain) and nucleocapsid (NP) proteins separately; 94% of patients had anti-RBD IgM and 100% had anti-RBD IgG antibodies two weeks after disease onset [47] . Anti-NP antibodies were detected in a slightly lower number of patients (88% for NP-IgM and 94% for NP-IgG). In these studies, antibody tests have been performed using enzyme immunoassays. These assays detect antibodies regardless of their functionality and hence their results are more useful from diagnostic and epidemiological perspectives. Whether these virus-specific antibodies exert any protective effects is a question that ought to be answered by in vitro or in vivo assays which examine antibody functionality. Indeed, a study by Wang et al has shown that virus-specific IgG could co-exist with SARS-CoV-2 virus for long periods, indicating that antibodies might not be associated with viral clearance [48] . Neutralizing antibodies which have the ability to block the interaction between spike protein RBD with the receptor have been reported for SARS-CoV and MERS-CoV [49, 50] . Results of convalescent plasma-transfer studies (discussed below) have pointed to the presence of these antibodies in people recovering from COVID-19 infection [51] . Indeed, there is a report by Ju et al. showing that potent anti-SARS-CoV-2 spike RBD antibodies with neutralizing ability do exist in COVID-19 patients [52] [53] [54] . In addition to neutralizing activity, complement activation by virus-specific antibodies is another functionality that should be considered in the context of a humoral immune response. Activation of complement system through classical (i.e. antibody-mediated) or alternative/MBL pathways can have protective and/or pathogenic effects through generation of various chemotactic/inflammatory mediators. Evidence pointing to beneficial effects of complement pathway activation in coronavirus infections is indirect and comes from studies which have shown that some virus-encoded proteins have the ability to block complement proteins [55] . In contrast, there is ample evidence indicating that complement activation contributes to coronavirus pathogenesis. A study by Magro et al. has shown that complement activation enhances microvascular injury and thrombosis in COVID-19 cases [56] . Studies on complement C3-deficient mice have demonstrated that these animals display significantly less severe disease following infection with mouse-adapted SARS-CoV strains [57] . Indeed, blockade of C3a and C5a has been shown to exert therapeutic effects in coronavirus-induced lung injury. Anti-C5a antibodies have been reported to protect mice from the impairments induced by MERS-CoV [58, 59] . Gao et al. have shown that SARS-CoV-2 N protein binds to mannose associated serine protease 2 (MASP-2), resulting in aberrant C5 activation and aggravated inflammatory lung injury [55] . The identification of complement proteins, MBL and, MASP-2 in the serum of COVID-19 patients is of paramount importance since in the event that the gravity of the disease intensifies with high concentrations of these proteins, mitigation of pathogenesis should be conducted by complement-targeted therapies. Additionally, assigning the severity of COVID-19 sufferers to high prevalence of genotypes with low MBL levels can further pave the way for detecting vulnerable populations. attributing a protective role to RBD-specific antibodies, commonly elicited from the majority of individuals convalescent from SARS-CoV-2, against reinfection even though, temporarily [60] . Unlike the observed delayed SHM (somatic hypermutation) in Ebola patients, the diagnostically confirmed SARS-CoV-2 infected patients manifested clear-cut polyclonal responses with early class switching to IgG, and on a smaller scale, IgA isotypes, as well as evidence of amassing SHM in responding clones within the initial month following the emergence of symptoms in their IGH (Immunoglobulin heavy chain) repertoires [60, 61] . The chief target of potent neutralizing antibodies, convergent IGH specific for the viral RBD, was detected in nine out of 13 COVID-19 patients (69%). As determined by the severity of disease, neutralization assay, and threshold for positive results [62] [63] [64] , the presence of SARS-CoV-2 neutralizing serum antibodies is confirmed in 67%-90% of patients post-infection. Thus, the prospect of developing spike or RBD antigen based vaccines capable of stimulating B cells for the expression of these common antibody types for a hefty proportion of the human population seems plausible [65] . The phenomenon named "antibody-dependent enhancement" (ADE) refers to a process whereby binding of a non-neutralizing antibody facilitates virus entry into the cells, and is likely to contribute to increased viral replication and virulence. This phenomenon has been reported for many viruses, including coronaviruses [62] . In the case of SARS-CoV, antibodies against spike protein are known to mediate this effect [66, 67] . Whether antibodies produced anti-SARS-CoV-2 or cross-reactive antibodies produced against other coronaviruses might be involved in COVID-19 pathogenesis is a possibility that needs to be investigated [68] . Virus-specific CD8 + cytotoxic cells represent the effector part of cell-mediated immunity against viruses. However, their activity, as well as the activity of B cells, is closely regulated by CD4 + T helper cells, which are further divided into Th1, Th2, Th9, Th17 and Treg functional phenotypes [69] . Information regarding protective cellular immune responses in COVID-19 is limited. However, some inferences can be made from studies on lymphocyte subset frequency [70, 71] . Analysis of peripheral blood cells in COVID-19 patients has shown reduced numbers of CD4 + and CD8 + T cells, B cells and NK cells, especially in more severe cases [72] . An increase in the numbers of CD8 + T cells and B cells has been seen in patients who respond to treatment, but not in non-responders [72] . These decreased numbers do not necessarily mean reduced cell activity. Immunophenotyping with cell activation markers on a single patient with reduced CD4 + and CD8 + T cells counts has revealed that these cells could be in a hyper activated state, as indicated by high numbers of HLA-DR/CD38 double-positive CD4 + T cells, increased frequency of proinflammatory CCR6 + Th17 cells, and higher percentage of granulysin and perforin positive CD8 + T cells [3] . Terminally differentiated CD8 + T cells or apparently exhausted CD8 + T cells are reported to be concomitant with a hike in expression levels of the inhibitory receptors programmed cell death protein-1 (PD1), T Cell Immunoglobulin Mucin-3 (TIM3), Lymphocyteactivation gene-3 (LAG3), Cytotoxic T-lymphocyte-associated protein-4 (CTLA4), NKG2A and CD39 in severe cases of the disease [73] [74] [75] [76] [77] . However, whether the expression of these receptors is merely a reflection of their recent activation calls into question the exhausted or the highly activated nature of the T cells in patients with COVID-19. Moreover, CD4 + T cells specific for the SARS-CoV-2 spike protein, possessing a Th1 cell cytokine profile, have been pinpointed in acute infections [78] . T helper 2 ( Th2 ) cell retains its normal responses in patients with mild symptoms despite its ambiguous responses in severe COVID-19 cases [75] . In view of the leading role of Th2 cell responses in a number of lung diseases, further studies can consider it as a focal point of extensive exploration. It is not clear how effective these CD4 + and CD8 + T cell subsets are in protection against COVID-19 infection. This would require functional studies on virus-specific T cell subsets. Evidence from animal studies on SARS-CoV shows that CD4 + T cell depletion might lead to decreased pulmonary recruitment of lymphocytes, lower titers of neutralizing antibodies and decreased production of cytokines. CD4 + T celldepleted animals have delayed clearance of SARS-CoV from lungs and more severe pneumonitis. In contrast, CD8 + T cell depletion in these mice did not influence viral replication or clearance [79] . give rise to the formation of protective T cell memory. Although the results of several trials are needed to substantiate the validity of the data on vaccination, early data gathered from COVID-19 survivors are auspicious, with memory CD4 + T cells and CD8 + T cells accounting for 100% and 70% of convalescents, respectively [80] . Furthermore, numerous SARS-CoV-2 proteins, including not only spike protein but also nucleoprotein and membrane protein evinced memory T cell responses [81] . While COVID-19 was initially recognized as a virus-induced respiratory disease, the understanding that it was associated with immune alterations, beyond what is seen in a viral pneumonia, took shape from the very first reports that indicated changes in leukocyte numbers, inflammatory markers and response to therapy. Further cell and molecular analyses demonstrated the profound and pervasive nature of COVID-19 immune dysregulation. Studies also revealed that these immune alterations are not merely an association, as it might occur in a systemic infection, but, very likely, the core pathogenic element of COVID-19. While developing effective antiviral therapies as well as prophylactic vaccines is of immense importance for controlling COVID-19, elucidating the precise nature of these immune dysregulations and devising strategies to control them, might be as critical. As indicated above, evidence regarding immune dysregulation in COVID-19 can be categorized to two types: evidence indicating that widespread immune dysregulation occurs in COVID-19 and is associated with disease severity, and evidence indicating that immune dysregulation is indeed the driving force behind COVID-19 pathogenesis, morbidity and mortality. As discussed below, evidence of the first type (i.e. association) is mainly based on cell and molecular studies but the second type of evidence has a more clinical nature. The first set of findings pointing to immune alterations in COVID-19 came from routine blood cell counts which showed that the majority of patients had leukocytosis, lymphopenia and enhanced neutrophil-to-lymphocyte ratio (NLR) [70, 71] . These initial findings were followed by immunophenotyping and functional analyses of leukocyte subsets, as well as molecular studies, in COVID-19 cases. Qin et al. performed a study on 452 COVID-19 patients, including 286 severe cases, in Wuhan, China. Consistent with initial reports, they detected higher leukocyte numbers, lower lymphocyte counts and, higher NLR in severe cases [82, 83] . Immunophenotyping with T, B and, NK cells markers demonstrated that the numbers of CD3 + T cells were decreased in severe cases, but the numbers of CD19 + B cells and CD56 + NK cells were not significantly different. Analysis of T lymphocyte subsets revealed significantly lower numbers of CD4 + T cells and CD8 + T cells, in severe cases compared with non-severe patients. Within CD4 + T cells, percentage of CD45RA + naïve T cells were higher in severe cases, but the percentage of CD45RO + memory cells were lower. Interestingly, numbers of Treg were significantly lower in severe cases. This was associated with a non-significant decrease in the numbers of induced Treg cells [82] . Another study by Chen et al. that was performed on a smaller group of patients (11 severe and 10 moderate cases), showed T cell lymphopenia and decreased absolute numbers of CD4 + as well as CD8 + T cells [84] . cells and NK cells [85] . Another study by Zheng et al. also reported decreased numbers of NK and CD8 + T cells in COVID-19 cases [71, 76] . Interestingly, this study showed that the expression of NKG2A, an inhibitory member of NKG2 family of receptors, was enhanced at the surface of NK and CD8 + T cells in COVID-19 patients. This was associated with lower levels of IFNγ, granzyme B and CD107 expression in these cells, altogether pointing to the development of an exhausted phenotype. In contrast to healthy controls, the upregulated transcripts of exhaustion markers, LAG3 and Hepatitis A virus cellular receptor 2 (HAVCR2) were noted through the scRNA-seq analysis of PBMCs from COVID-19 patients [86] . The compelling evidence to validate the functional exhaustion of peripheral NK cells during COVID-19 infection. Whether a constant shrink in the number of peripheral NK cells emanates from NK cell trafficking to infected tissues or cell death in severe COVID-19 cases remains unsettled [76, 85, 87] , it is unclear whether this decrease is due to NK cell trafficking to infected tissues or cell death. NK cells remaining in the periphery might not contribute to proinflammatory cytokine production but instead have an exhausted phenotype that could facilitate virus dissemination to other sites of the body. The NK cells lingering in the periphery may not be held responsible for engendering proinflammatory cytokine; however, their exhausted phenotype can boost virus dissemination to other parts of the body [71, 88] . As discussed above, lymphopenia is a characteristic finding in COVID-19 cases. However, mechanisms of SARS-CoV-2 induced lymphopenia are not clear. In general, lymphopenia can occur by three different mechanisms: 1) decreased production of lymphocytes or lymphopoiesis; 2) apoptosis and destruction of lymphocytes, and 3) lymphocyte redistribution through attachment and emigration of lymphocytes through endothelial cells (similar to neutrophil margination and efflux) [89] . In theory, viral infections can influence the number of circulating lymphocytes by any of these mechanisms. Infections which lead to cytokine storms can activate the hypothalamic-pituitaryadrenal axis (HPA) and cause lymphopenia as consequence of increased glucocorticoid levels. Glucocorticoids reduce lymphocyte production in primary lymphoid organs and induce apoptosis in lymphocytes [90, 91] . Some viruses directly target lymphocytes (e.g. HIV, VZV, and polio) and cause lymphopenia independent of systemic cytokine responses [92] . However, there is no evidence that SARS-CoV-2 induced lymphopenia is associated with this mechanism. Regardless of the mechanism, lymphopenia and enhanced NLR are highly correlated with COVID-19 disease severity/outcome. On the other hand, the presence of lymphocytes in patients' lungs and scRNA-seq of bronchoalveolar lavage fluid (BALF) is unearthed by autopsy studies, despite this, the lymphocytic infiltration is shown to be scant [93, 94] . In addition, the patients with acute cases compared to those with moderate ones manifested a radically reduced contribution of cytotoxic T lymphocytes based on a recent scRNA-seq inspection of the upper respiratory tract [95] . T cell depletion can thus be attributed to either the hyperactivation of T cells or high levels of expression of pro-apoptotic molecules, such as FAS (also known as CD95) [96] , TRAIL or caspase 3 [75] . An issue which is worth investigating is whether SARS-CoV-2 induced lymphopenia is merely a disease epiphenomenon or that it is a driving force in disease pathogenesis. [85] . Classic MAS is a status of immune hyper activation which is mostly recognized in the context of autoimmune diseases and/or malignancies [97] . There are reports that a MAS-like syndrome occurs in cases of sepsis where it is characterized by hyper activation of tissue macrophages and overproduction of IL1β, IL18 and Ferritin [98] . In the report by Giamarellos-Bourboulis et al. authors have categorized immune perturbations in severe COVID-19 cases to two groups, a group where immune dysregulation is mainly driven by IL6, and a MAS group where IL1β is the key player behind immune dysregulation. Both groups display elevated levels of proinflammatory cytokines, nonetheless, the first group demonstrates higher IL6 levels, decreased levels of CD14 on monocytes and CD4 + lymphopenia, whereas the latter displays higher levels of IL1β, ferritin and high scores for hemophagocytosis [85] . Cytokine its correlation with disease severity has been reported by different groups [111] [112] [113] . Several mechanisms have been proposed for SARS-CoV-2 induced cytokine storm [112] . species) with PRRs is perhaps the main mechanism for extensive innate immune activation in COVID-19 [114, 115] . However, the fact that SARS-CoV-2 (and SARS-CoV) interact with ACE2 receptor for cell entry likely adds another dimension to the cytokine storm induced by these viruses. Following binding of the virus to ACE2, the receptor gets endocytosed together with the virus. This leads to diminished levels of ACE2 at the cell surface. ACE2's physiological function is to inactivate angiotensin II (AII) molecules produced by ACE, and hence its downregulation leads to enhanced levels of AII in circulation [116] . AII is generally known for its vasoconstrictive activities, but it also acts as a potent proinflammatory cytokine [117, 118] Knowledge regarding potential immunotherapies for COVID-19 is still evolving. Similar to pathogenesis, part of this knowledge is derived from studies on two other highly pathogenic coronaviruses, SARS-CoV and MERS-CoV. Controlling CRS seems to be critical for improving the outcome of COVD-19. Treatment with systemic corticosteroids is generally the first option for physicians to control the severity of a systemic inflammation. Studies on SARS-CoV and MERS-CoV have shown positive effects for corticosteroids in these infections. However, reports exist that, while initially beneficial, corticotherapy might lead to increased viral load in patients [122, 123] . Data regarding the usefulness of corticosteroids in COVID-19 is controversial [124] . Some findings suggesting that low to moderate doses of dexamethasone (decadron) and methylprednisolone could lower the mortality rate in patients with a severe form of the condition. It is, however, not recommended for patients with mild/moderate symptoms (non-severe). However, the vast use of corticosteroids was not advocated for, as high doses of the drug can cause more adverse than useful [125] . Type I interferons are known for their antiviral as well as immunomodulatory properties and interferon therapy has long been used for the treatment of chronic viral infections [126] . in combination with antiviral agents [127] . Likewise, studies on a primate (marmoset) model of MERS have shown the effectiveness of interferon-β1b on disease outcome [128] . Combination of interferon-α2b and ribavirin has reduced viral replication and inflammatory response in MERS-CoV infected macaques [129] . Fewer reports exist for interferon therapy in SARS-CoV. A preliminary study on SARS-CoV patients reported better outcome for patients receiving a combination of interferon-alfacon1 and corticosteroids, compared with patients treated with corticosteroids alone [130] . It has been suggested that treatment with interferonlambda (IFN-λ), a type III interferon with antiviral effects, might be appropriate for COVID-19 patients and it should be considered in clinical trials [131, 132] . Unlike type I interferons, interferon-lambda acts through receptors that are not expressed on resting immune cells, helping to diminish systemic pro-inflammatory effects [132] . On the basis of the studies conducted by Bastard et al. neutralizing auto-Abs against type I IFNs is detected in merely 10% of terminally ill patients with COVID-19 pneumonia [133] . Up until the infection with COVID-19 and the subsequent subtle stimulation of type I IFNs, such auto-Abs remain silent [27] , implying that protection against severe disease can be attained upon the induction of slight quantities of IFNs by the virus. These findings could bearings on clinical purposes. First, the convalescent plasma of such patients should be precluded from the proceeding clinical trials, or at least be screened prior to donation [134] . Second, as a consequence of this discovery, plasmapheresis, monoclonal Abs depleting plasmablasts, and the specific inhibition of type I IFN reactive B cells can be implemented as therapeutic interventions [135] . Finally, in this patient group, although early treatment with IFN-α seems futile, treatment with injected or nebulized IFN-β is projected to be fruitful due to the scarcity of auto-Abs against IFN-β in patients with auto-Abs against type I IFNs [133] . Passive immunotherapy with antibodies has long been used in viral infections for prophylactic and, less frequently, therapeutic purposes. Plasma obtained from vaccinated patients or patients recovering from a viral disease have been the main source of potentially protective polyclonal antibodies (pAbs), while anti-viral murine or humanized monoclonal antibodies (mAbs) or their fragments have been usually produced by experimental methods. Following exposure to a pathogen, various antibodies that target different microbial antigens are produced by humoral immune system; however, the majority of these antibodies might not yield any protective effects. For the antibodies to exert protective effects they need to target particular antigenic determinants with sufficient affinity. Studies on SARS-CoV and MERS-CoV have shown that antibodies which target domains in the spike protein are more likely to be protective [136] . Spike protein contains an N-terminal S1 subunit and a C-terminal S2 subunit. S1 subunit which is responsible for virus receptor binding is composed of two domains; a receptor binding domain (RBD) and an N-terminal domain (NTD). S2 subunit mediates membrane fusion [136] . Antibodies against S1RBD, S1NTD and S2 domains/subunit have been reported to have neutralizing effects against SARS-CoV and MERs-CoV; nonetheless, the majority belongs to anti-RBD antibodies [137] . Various neutralizing monoclonal antibodies have been reported for SARS-CoV (e.g. through screening an antibody phage library from a convalescent SARS-CoV patient [146] has been shown to bind to SARS-CoV-2 spike RBD with a KD of 6.3 nM [147] . Interestingly, a crystallographic study on CR3022-RBD complex has indicated that CR3022 does not interact with the receptor binding site of RBD [148] . Other SARS-CoV nAbs (i.e. m396 and CR3014) have also been examined but they do not bind to SARS-CoV-2 spike, perhaps due to differences in antigenic determinants between spike proteins [147] . While using mono/polyclonal antibodies with neutralizing abilities seems a plausible option for COVID-19 treatment. Studies on animal models of SARS-CoV have shown that presence of anti-Spike IgG could increase proinflammatory responses in the lung, perhaps through increased production of chemokines (i.e. IL8 and MCP1) and further recruitment of monocytes/macrophages [149] . Of interest, blocking FcγR by anti-CD64 antibodies decreased proinflammatory effects induced by anti-Spike antibodies [149] . These findings indicate that to harness the protective effects of nAbs, deliberate changes in the structure of the antibody or production of antibody fragments (i.e. Fab or ScFv) might be necessary. Increased chances of antibody escaping mutants and enhanced 'resistance' to antibody cocktails can emanate from the relatively swift mutation rate of SARS-CoV-2 (as an RNA virus) [150] [151] [152] . Therefore, the administration of a cocktail of Currently, the efficacy of these and other vaccine modalities are constantly being scrutinized for immunization against COVID-19. Convalescent plasma (CP) has been used for prophylactic and/or therapeutic purposes in infectious diseases for more than a century. Before the emergence of SARS-CoV-2, CP therapy had shown promising results in SARS and MERS patients, with treated patients exhibiting reduced disease severity and viral loads [155, 156] . Plasma samples were obtained from 39 COVID-19 cases who had recently recovered from disease, and whose neutralizing antibody titers were above 1:160 [158] . CP-receiving patients showed significant improvement in clinical symptoms and PO 2 levels within 3 days after transfusion. This was associated with improvement in radiological findings, increase in lymphocyte counts and decrease in C-reactive protein (CRP) levels [159] . Similar to the previous study, titers of neutralizing antibodies rose in some of the patients [158] . It should be noted that prophylactically (compared with therapeutic uses). This adds to the potential value of this approach, at least until a vaccine becomes available. IVIg treatment has been used in various immune-related disorders, including immunodeficiencies, autoimmunities, chronic inflammatory disorders and infectious diseases. When used in the context of viral infections associated with systemic inflammation, IVIg might act through two mechanisms; providing the patient with a pool of potentially cross-protective antibodies, and promoting immune regulation. The latter takes place through multiple pathways, including the blockade of proinflammatory mediators, FcγRs and leukocyte adhesion molecules, influencing T cell differentiation and neutralization of harmful autoantibodies [160, 161] . Studies on SARS have indicated some beneficial effects of IVIg treatment. In a study by Wang et al. IVIg therapy on SARS patients with severe leukopenia and thrombocytopenia improved leukocyte/platelet counts [162] . Treatment with IgMenriched IVIg has shown some benefit in SARS cases who had not responded to corticosteroid or ribavirin therapy [163] . Nonetheless, a systematic review of treatment strategies in SARS did conclude that, overall, the result of IVIg therapy in SARS were inconclusive [164] . At the moment, thanks to seven reports such as the [167] . The therapeutic yields of IVIg in these trials are so elusive to be assessed due to the existence of corticosteroid combination. Another study combined IVIg with Anakinra, a recombinant modified IL1 receptor antagonist [170] . Thus, the therapeutic benefits of IVIg have to be probed even more meticulously due to the eclectic nature of therapies. Quite identical to COVID-19, other stumbling blocks such as the outbreak of autoimmune and inflammatory diseases including Kawasaki-like pediatric inflammatory multisystemic syndrome, Guillain-Barré syndrome and idiopathic thrombocytopenic purpura are inextricably associated with SARS-CoV-2 infection. IVIg is proved as a potent therapy in these SARS-CoV-2 infections associated with scarce pathological manifestations [171] [172] [173] . [174, 175] in order to further shed light on the advantages of additive or synergistic therapies. In addition to its protective effects against Mycobacterium tuberculosis, BCG vaccine is known to exert general effects on the function of immune system. Analyses of innate immune cells (i.e. monocytes/macrophages) following BCG vaccination have shown that these cells develop an increased TNFα, IL1β and IL6 response to pathogens unrelated to mycobacteria, and express higher levels of PRRs, including TLR4 and mannose receptor [176] . Molecular studies have shown genome-wide epigenetic alterations in these cells following BCG vaccination [177] . These epigenetic and transcriptional changes are believed to underlie a particular type of innate immune memory; which, unlike adaptive immune memory, does not involve antigen-specific stimulation of lymphocytes. Some authors have used the phrase "trained immunity" to refer to these changes [178] [179] [180] . The possibility that BCG vaccination might have protective effects against COVID-19 has been raised in several reports, mostly based on epidemiological data, indicating that COVID-19 mortality has a negative correlation with the extent of BCG vaccination in different countries [181] [182] [183] [184] . Multiple clinical trials are underway to examine any possible relations between BCG vaccination and COVID-19 more precisely (NCT04328441, NCT04379336 and NCT04327206). Mesenchymal stem cells (MSCs) are known to possess immunomodulatory properties and treatment with these cells has been extensively investigated in the context of infectious and non-infectious inflammatory disorders [185] . Widespread inflammation in COVID-19 suggests that inhibitors of proinflammatory cytokine signaling might be of therapeutic value. Tocilizumab, an IL6 receptor blocking mAb, is an approved medicine for the treatment of rheumatoid arthritis as well as CAR-T cell related CRS. The first set of evidence pointing to the usefulness of Tocilizumab in COVID-19 came from a series of case reports [187] [188] [189] [190] . These case reports were followed by investigations on higher numbers of patients. [192] . In another study analyzed the clinical characteristics and outcomes of 96 patients with severe to critical COVID-19 disease who received a single dose of the IL6 inhibitor Tocilizumab as part of their treatment. This ranged from 16% in non-intubated patients to 71% in those who required intubation and mechanical ventilation. This data showed a non-significant trend toward lower mortality in patients with severe to critical COVID-19 disease treated with Tocilizumab. When intubated patients were excluded, those who received Tocilizumab had lower mortality [193] . Other inhibitors of cytokine signaling are being considered for their potential therapeutic effects in COVID-19. Of note, in a report by Aouba et al. researchers examined the effects of Anakinra, a modified version of interleukin 1 receptor antagonist, in nine moderate to severe COVID-19 cases. Of these, eight patients showed improvements at clinical and laboratory levels [194] . an AI-generated repository of medical information, to look for agents which could block this process. They focused on AAK1 (AP2-associated protein kinase 1), a regulator of receptor-mediated endocytosis. Their search led them to Baricitinib, an inhibitor of AAK1, which is also a Janus-kinase inhibitor [195] . Interestingly, a later study by Cantini et al. on 12 moderate COVID-19 cases showed that Baricitinib could improve clinical and laboratory parameters in patients within 2 weeks [196] . Whether this effect was due to Barcitinib's AAK1/endocytosis inhibiting activity or its role in blocking cytokine signaling is not known. A grave global public health emergency has arisen from dysfunctional immunity of In this review article, we discussed three different aspects of COVID-19 immunology; immune response against the virus, attributes and mechanisms of immune dysregulation (Figure 1 ), and possible strategies for immunotherapy ( Figure 2 ). Due to the recent emergence of this infection, our understanding of these aspects of COVID-19 is still evolving. Nonetheless, available data have revealed the fact that, while COVID-19 manifests as a respiratory disease, it is probably better explained as a virus-induced immunopathology. In addition to efforts for developing antiviral agents and protective vaccines, understanding the intricacies of virusimmune system interaction seems essential for proper management of disease. Although many ambiguities remain unsettled in this regard, this focused review is an attempt to summarize the focal points of current attainments concerning the immune correlates of COVID-19 gravity and resolution with the aim of assisting researchers in the field to contemplate on novel avenues in prevention and control. The authors declare no competing financial interests. Clinical characteristics of coronavirus disease 2019 in China Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) Pathological findings of COVID-19 associated with acute respiratory distress syndrome Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease COVID-19 and the cardiovascular system Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality A pneumonia outbreak associated with a new coronavirus of probable bat origin Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study Nervous system involvement after infection with COVID-19 and other coronaviruses Implications of COVID-19 for patients with pre-existing digestive diseases Caution on kidney dysfunctions of COVID-19 patients Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The lancet Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Clinical characteristics of coronavirus disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in COVID-19 infection: the perspectives on immune responses Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients A pathological report of three COVID-19 cases by minimally invasive autopsies, Zhonghua bing li xue za zhi= Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6 Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro SARS and MERS: recent insights into emerging coronaviruses Imbalanced host response to SARS-CoV-2 drives development of COVID-19 Dysregulation of type I interferon responses in COVID-19 Induction of IL-8 release in lung cells via activator protein-1 by recombinant baculovirus displaying severe acute respiratory syndrome-coronavirus spike proteins: identification of two functional regions Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome Multiple organ infection and the pathogenesis of SARS Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells HLA and infectious diseases The MHC locus and genetic susceptibility to autoimmune and infectious diseases Polymorphism of HLA class I and class II alleles in influenza A (H1N1) pdm09 virus infected population of Assam Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection Association of human leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection Human leukocyte antigen susceptibility map for SARS-CoV-2 Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis Antibody responses to SARS-CoV-2 in patients with COVID-19 Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19 Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses Covid-19: FDA approves use of convalescent plasma to treat critically ill patients Recombinant adenoviral vaccine encoding the spike 1 subunit of the Middle East Respiratory Syndrome Coronavirus elicits strong humoral and cellular immune responses in mice Human antibodies can neutralize SARS-CoV-2 Human neutralizing antibodies elicited by SARS-CoV-2 infection Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis B cell clonal expansion and convergent antibody responses to SARS-CoV-2 Longitudinal analysis of the human B cell response to Ebola virus infection Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals, bioRxiv Rapid generation of neutralizing antibody responses in COVID-19 patients Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2 Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus Is COVID-19 receiving ADE from other coronaviruses? T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV Clinical features of patients infected with 2019 novel coronavirus in Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia Comprehensive mapping of immune perturbations associated with severe COVID-19 Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis Functional exhaustion of antiviral lymphocytes in COVID-19 patients Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 Dysregulation of immune response in patients with COVID-19 in Wuhan, China Comparison of clinical, para-clinical and laboratory findings in survived and deceased patients with COVID-19: diagnostic role of inflammatory indications in determining the severity of illness Clinical and immunological features of severe and moderate coronavirus disease 2019 A single-cell atlas of the peripheral immune response in patients with severe COVID-19 Dysregulation of the immune response in coronavirus disease 2019 Functional exhaustion of antiviral lymphocytes in COVID-19 patients Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS Immune modulation of the hypothalamicpituitary-adrenal (HPA) axis during viral infection The hypothalamic-pituitary-adrenal axis and viral infection Principles and practice of pediatric infectious diseases Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Macrophage activation syndrome and cytokine-directed therapies, Best practice & research Giamarellos-Bourboulis, Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome On the alert for cytokine storm: Immunopathology in COVID-19 Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses SARS-CoV regulates immune function-related gene expression in human monocytic cells Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing Heightened innate immune responses in the respiratory tract of COVID-19 patients Immunopathological characteristics of coronavirus disease 2019 cases in Middle East respiratory syndrome: emergence of a pathogenic human coronavirus, Annual review of medicine Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology COVID-19: Immunology and treatment options COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain ACE and ACE2 in inflammation: a tale of two enzymes Angiotensin II in inflammation, immunity and rheumatoid arthritis Angiotensin II revisited: new roles in inflammation, immunology and aging A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirusinduced lung injury Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis, medRxiv Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review Interferons and viral infections Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study COVID-19: lambda interferon against viral load and hyperinflammation COVID-19 and emerging viral infections: The case for interferon lambda Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population Functional diversification of IgGs through Fc glycosylation The spike protein of SARS-CoV-a target for vaccine and therapeutic development Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants Ultrapotent human neutralizing antibody repertoires against Middle East respiratory syndrome coronavirus from a recovered patient Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection Passive transfer of a germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal Middle East respiratory syndrome coronavirus infection Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients Emergence of genomic diversity and recurrent mutations in SARS-CoV-2, Infection Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis A review of treatment modalities for Middle East respiratory syndrome Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Convalescent plasma treatment of severe COVID-19: a propensity scorematched control study Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients Pentaglobin in steroid-resistant severe acute respiratory syndrome SARS: systematic review of treatment effects Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A multicenter retrospective cohort study High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19 Anakinra and intravenous IgG versus tocilizumab in the treatment of COVID-19 pneumonia Autoimmune and inflammatory diseases following COVID-19 Molecular and immunological biomarkers to predict IVIg response Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic Anakinra for severe forms of COVID-19: a cohort study Tocilizumab in patients with severe COVID-19: a retrospective cohort study Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity Non-specific effects of vaccines illustrated through the BCG example: from observations to demonstrations BCG-induced protection: effects on innate immune memory Considering BCG vaccination to reduce the impact of COVID-19 Could BCG be used to protect against COVID-19? Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study, medRxiv Differential COVID-19-attributable mortality and BCG vaccine use in countries, medRxiv Treatment of inflammatory diseases with mesenchymal stem cells Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia First case of COVID-19 treated with tocilizumab in Iceland Dramatic improvement after Tocilizumab of a severe COVID-19 in a child with sickle cell disease and acute chest syndrome A Recovered Case of COVID-19 Myocarditis and ARDS Treated with Corticosteroids, Tocilizumab, and Experimental AT-001 The many faces of the anti-COVID immune response Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19 Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a casecontrolled study Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact The authors acknowledge the Tehran University of Medical Sciences for financial support.